The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks renewal of its National Cancer Institute (NCI) designation awarded in 2009 via the P30 Cancer Center Support Grant (CCSG) mechanism. As South Carolina's leading academic medical center, MUSC is charged with building clinical, basic, translational, and population-based research programs that address the state's significant healthcare needs. The mission of the HCC is to reduce the cancer burden in South Carolina. To accomplish this mission, the Director, Dr. Andrew S. Kraft, and the HCC senior leadership have established a robust, interdisciplinary base that now includes 122 cancer scientists from 5 MUSC colleges and 20 academic departments. Interdisciplinary, innovative research is driven through the organization of the HCC into four programs: Cancer Genes & Molecular Regulation, Cancer Immunology, Developmental Cancer Therapeutics, and Cancer Control. The rapid pace of discovery and movement toward effective translational research is supported by shared research resources, five of which are presented in this application: Lipidomics, Cell Evaluation & Therapy, Cell & Molecular Imaging, Biorepository & Tissue Analysis, and Biostatistics. The HCC also seeks CCSG support for its Clinical Trials Office which has spear-headed a dramatic 59% increase in accrual volume for interventional treatment trials over the last four years. Notably, 26% of patients enrolled onto interventional treatment trials in 2012 were minorities, representing a 45% increase in this project period. This has been promoted by HCC-led progressive outreach services and cancer education to South Carolinians, a largely rural population that includes some of the most medically underserved people in the US. Today, the HCC has $40.8M in annual total extramural research funding with $18.6M derived from the NCI, representing a 31% and 54% increase respectively since 2009. The HCC has successfully leveraged CCSG funding during the first project period and its NCI-designated Cancer Center status to continue the rapid growth of this Center. During the current project period the HCC supported 34 strategic recruitments to the Center. The opening of two state-of-the-art research facilities at MUSC, the Bioengineering and Drug Discovery Buildings, has resulted in an additional 66,156 ft2 of HCC research space, bringing the total amount of space on campus under the HCC authority to 270,174 ft2. The HCC has invested $5.3M since 2009 to introduce cutting-edge technologies and has secured another $3.8M in institutional commitments to increase the range of available resources. These impressive developments ensure that HCC scientists will continue their exemplary track record in making significant contributions to the understanding of cancer biology while coupling these findings to the development of novel approaches to cancer control, diagnosis, and treatment.

Public Health Relevance

The Hollings Cancer Center coordinates scientific research to promote interdisciplinary collaborations and translation of cancer research from the 'bench to bedside to community' and provides outstanding shared research resources in support of its scientists, with the goal of reducing the cancer burden in South Carolina.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138313-08
Application #
9042248
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
2009-04-01
Project End
2019-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
8
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Joseph, Anne M; Rothman, Alexander J; Almirall, Daniel et al. (2018) Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 197:172-182
Rojewski, Alana M; Tanner, Nichole T; Dai, Lin et al. (2018) Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. Chest 154:110-118
Ramshesh, Venkat K; Lemasters, John J (2018) Imaging of Mitochondrial pH Using SNARF-1. Methods Mol Biol 1782:351-356
Kim, Myung Jong; Jeon, Sohee; Burbulla, Lena F et al. (2018) Acid ceramidase inhibition ameliorates ?-synuclein accumulation upon loss of GBA1 function. Hum Mol Genet 27:1972-1988
Chatterjee, Shilpak; Chakraborty, Paramita; Daenthanasanmak, Anusara et al. (2018) Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res :
Jiang, Yu Lin; Zhu, Yun; Moore, Alfred B et al. (2018) Biotinylated Bioluminescent Probe for Long Lasting Targeted in Vivo Imaging of Xenografted Brain Tumors in Mice. ACS Chem Neurosci 9:100-106
Carrell, Rebecca K; Stanton, Rebecca A; Ethier, Stephen P et al. (2018) ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen. Vaccine 36:6262-6269
Zhou, Yue; Li, Pengfei; Goodwin, Andrew J et al. (2018) Exosomes from Endothelial Progenitor Cells Improve the Outcome of a Murine Model of Sepsis. Mol Ther 26:1375-1384
Zhong, Zhi; Lemasters, John J (2018) A Unifying Hypothesis Linking Hepatic Adaptations for Ethanol Metabolism to the Proinflammatory and Profibrotic Events of Alcoholic Liver Disease. Alcohol Clin Exp Res 42:2072-2089
Sizemore, Gina M; Balakrishnan, Subhasree; Thies, Katie A et al. (2018) Stromal PTEN determines mammary epithelial response to radiotherapy. Nat Commun 9:2783

Showing the most recent 10 out of 536 publications